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Abstract 
 
 Mr Litvinenko died on 23rd November 2006, having been poisoned with 
polonium-210 on 1st November, with evidence of a previous poisoning attempt during 
October 2006. Measurements of 210Po in urine samples were made for a large 
number of people to determine whether they may have been contaminated. In the 
majority of cases, measured levels were attributable to the presence of 210Po from 
normal dietary sources. For a small number of cases, elevated levels provided 
evidence of direct contamination associated with the poisonings. For one individual, 
while estimated doses were below thresholds for irreversible organ damage, a 
notably increased risk of cancer can be inferred. The use of the chelating agent, 
Unithiol, to increase 210Po excretion in this case was only moderately effective in 
reducing doses received. 
 
  
1. Introduction  
 
Mr Alexander Litvinenko died on 23rd November 2006, following poisoning with 
polonium-210 on 1st November. The case has been the subject of a criminal 
investigation and a public inquiry chaired by Sir Robert Owen that reported on 21st 
January 2016 (www.litvinenkoinquiry.org). The clinical case history has recently been 
published (Nathwani et al 2016), with separate publication of associated details of 
assessments of intake of 210Po, organ doses and consequent rapid decline in 
physiological function leading to death (Harrison et al 2017). The results presented 
by Harrison et al (2017) include evidence of a previous poisoning attempt during 
October 2006. This paper considers the 210Po contamination of other individuals, 
principally on the basis of measurements on urine samples.      
 
Polonium-210 is an alpha particle (5.3 MeV) emitting radionuclide with a half-life of 
138 days. It is a naturally-occurring radionuclide, present in our diets, body tissues 
and excreta as a member of the uranium-238 decay chain. Dietary intake varies 
substantially so that urinary excretion is also variable (Hodgson 2017). Interpretation 
of urine measurements to assess the probability of contamination from artificial 
sources must therefore take account of natural levels and their variability.     
 
Polonium-210 contamination was found at the two London hospitals responsible for 
the care of Mr Litvinenko from 3rd November 2006, raising concerns that hospital staff 
may have become contaminated. The police investigation identified a number of 
contaminated locations, including parts of several hotels, restaurants, and office 
buildings. Twenty-four hour urine samples were taken from a large number of people 
judged to be at risk of contamination (over 800) in order to determine the extent of 
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any contamination (Bailey et al 2008, 2010, Maguire et al 2010). International follow-
up of persons potentially exposed was reported by Shaw et al (2010).   
 
The Litvinenko Inquiry was provided with reports on two additional contaminated 
individuals by an Expert Commission of the Federal Medical and Biological Agency 
(FMBA) of the Russian Federation. These reports provide measurements and 
interpretation for individuals referred to here as X (COM00181001) and Y 
(COM00182001) (www.litvinenkoinquiry.org).  
  
A detailed analysis of available data on natural concentrations of 210Po in urine 
(Hodgson 2017) is referred to here in the interpretation of measurements on urine 
samples taken in the UK during the months following Mr. Litvinenko’s death. Use is 
also made of the data provided by FMBA. Estimates of radiation dose are presented 
for the two individuals and interpreted in terms of possible risks to health. The 
efficacy of intramuscular injections of Unithiol in accelerating excretion is also 
considered on the basis of the data provided.  
  
 
2. Methods 
 
2.1. Radioactivity measurements 
 
A sensitive, but relatively rapid, method was developed to handle the large numbers 
of urine samples analysed during the poisoning incident response (Bailey et al 2008, 
2010). It required 2–3 days from receipt of a 24-hour urine sample. The method was 
adapted from one that is in routine operational use for measurements on 
environmental samples, e.g. food, and is therefore capable of measuring natural 
levels of 210Po in many types of sample, including urine. In summary, concentrated 
nitric acid was added to a 1-litre sample of urine to break down organic matter. The 
mixture was evaporated slowly (overnight), the residue dissolved in hydrochloric acid, 
and the 210Po spontaneously deposited onto a silver metal disc for counting using an 
alpha spectrometer (typically overnight). The minimum detectable activity (MDA) 
varied between measurements according to the efficiency of the recovery of 
polonium, which was determined by adding a known amount of a different polonium 
isotope (209Po or 208Po) at the start of the process, and measuring the amount 
present at the end. MDAs of 1 – 10 mBq d–1 were usually achieved, depending on 
recovery. Validation checks were performed with five laboratories in the UK and eight 
in other European countries. Some of these laboratories used different methods for 
the radiochemical isolation of polonium. The results obtained were all consistent. 
 
2.2. Estimates of radiation doses 
 
Bailey et al (2008, 2010) developed a methodology for dose assessment of the large 
number of results of urine measurements becoming available in the first weeks after 
it had been established that 210Po had been used to poison Mr Litvinenko and, that as 
a result, a number of places had been contaminated with 210Po. Essentially, three 
categories were identified: (1) urine measurements of < 30 mBq d-1 that were 
possibly attributable to natural background 210Po levels, (2) effective doses of < 1mSv 
estimated by the application of standard conservative assumptions, and (3) effective 
doses of > 1 mSv estimated using more realistic assumptions applied to individual 
cases. The estimation of effective dose depended on the use of biokinetic and 
dosimetric models developed by the International Commission on Radiological 
Protection (ICRP 1993, 1994a,b, 1996, 2006) and ICRP values of effective dose per 
Bq inhaled or ingested. The ICRP models were implemented using the computer 
codes, IMBA (Birchall et al 2007) and PLEIADES (Fell et al 2007).      
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Excretion rates of > 30 mBq d-1 were taken as indicative of possible intake of an 
artificial source of 210Po (see section 3.1). In all cases of recorded values > 30 mBq  
d-1, an initial rapid assessment of possible dose was made using a standard set of 
assumptions that were either realistic (an activity median aerodynamic diameter, 
AMAD, of 5 µm, moderate solubility of the aerosol in the respiratory tract (ICRP Type 
M), or tended to overestimate dose: intake entirely by inhalation rather than 
ingestion, acute intake on a fixed date as the earliest possible exposure rather than 
continuing chronic intake, and no subtraction of background levels attributable to 
natural 210Po (Bailey et al 2008). With these standard assumptions, a set of 
conversion factors were calculated for estimation of dose from measured activity, 
dependent only on the duration between the assumed date of intake and the date of 
sample collection. For all estimates > 1 mSv, a more detailed analysis was 
undertaken, in particular to take account of a more probable balance between intake 
by inhalation and ingestion (Bailey et al 2008, 2010).    
 
The data provided to the Litvinenko Inquiry by an FMBA Expert Commission in the 
Russian Federation (reports COM00181001 and COM00182001, 
www.litvinenkoinquiry.org) included measurements of 210Po activity in urine and 
faecal samples and estimates of organ doses for two individuals, identified here as X 
and Y. Doses have been reassessed, using ICRP models, together with the systemic 
biokinetic model developed by Leggett and Eckerman (2001). The data on urinary 
and faecal excretion have also been used to assess the efficacy of intramuscular 
injections of Unithiol in accelerating excretion.  
 
 
3. Results 
 
3.1 Natural background levels of 210Po in urine 
 
Hodgson (2017) presented a review and analysis of available data on background 
levels of 210Po in urine. It was determined that 819 measurements could be 
considered to correspond to natural background levels, excluding a large number of 
values identified by the authors as potentially due to an artificial source or due to 
recognised enhancement of dietary intake. Almost 550 measurements were 
extracted from studies reported in the literature (Black 1956, Globel et al 1966, 
DeBoeck et al 1971, Bale et al 1975, Okabayashi et al 1975, Juan and Balleos 1976, 
Holtzman et al 1976, Spencer et al 1977, Clemente et al 1979, Helmkamp et al 1979, 
Okabayashi et al 1982, Irlweck 1983, Mancini et al 1984, Azeredo & Lipsztein 1991, 
Hunt and Allington 1993, Santos et al 1994, Santos et al 1995, Naumann et al 1998, 
Santos et al 2000, Thomas et al 2001, Schafer and Seitz 2005, Hunt and Rumney 
2007, Manickam et al 2010). The additional measurements were contributions of 
previously unpublished data, acknowledged by Hodgson (2017). The analysis of the 
measurements gave mean and median values of 14 mBq d-1 and 9 mBq d-1, 
respectively. Although not conforming statistically to a log-normal distribution, the 
majority of the measurements were found to be tightly clustered around the mean 
and median values but with a long asymmetric tail to the distribution. While the 
overall range was from 0.3 to 170 mBq d-1, more than 90% of the measurements 
corresponded to excretion rates less than 30 mBq d-1, 95% were less than 45 mBq  
d-1 and 99% less than 70 mBq d-1.  
Separate analysis of data for smokers and non-smokers suggested a modest 
increase in smokers of up to around 5 mBq d-1. Reflecting the importance of dietary 
differences such as seafood consumption, a marked difference between countries 
was observed in the range of results (Hodgson 2017). While for most countries, 95% 
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or more of results were below 30 mBq d-1, China and Italy were notable exceptions, 
with greater than 20% of values above this level.      
3.2. UK Measurements to assess possible contamination in London during 2006 
The majority of the measurements of excretion rates (total of around 800) were below 
30 mBq d-1 and were most probably due to natural levels of 210Po in diet, providing no 
evidence of exposure to an artificial source. The majority of measurements above 30 
mBq d-1 were assessed as corresponding to an effective dose of less than 1 mSv (86 
cases identified by Bailey et al 2008, 2010). A total of 36 cases for which more 
detailed assessments were undertaken had estimated doses within the range of 1 – 
6 mSv (Bailey et al 2010) or a total of 43 in the range 1 – 10 mSv. Doses in the range 
> 10 mSv – 100 mSv were recorded for a total of 8 people, mostly staff of one hotel.     
3.3. Russian Federation measurements to assess contamination for two cases   
Assessments of intake and radiation doses have been made for comparison with 
those reported by FMBA.  The results used were measurements on urine, blood and 
faecal samples taken prior to the administration of Unithiol to increase excretion. 
Estimates of 210Po intake by individuals X and Y were made separately for each 
sample taken – urine, faeces and blood. As shown in Tables 1 and 2, estimates vary 
according to the assumed date and route of intake, and between the samples on 
which they are based. Values for X average about 4 MBq for either ingestion or 
inhalation on 1.11.06 and 6 – 7 MBq for ingestion or inhalation on 16.10.06 (Table 1). 
Values for Y are estimated to be an order of magnitude lower (Table 2).  
 
Ratios of urinary to faecal excretion (U/F) for samples measured prior to 
administration of Unithiol were compared with model predictions to determine 
whether any conclusions could be drawn regarding route of intake. However, while 
difference in U/F ratios between inhaled and ingested 210Po would be expected at 
shorter times after an intake, predicted values corresponding to the times of sample 
collection showed that there was not a large difference between expected ratios 
following inhalation and ingestion at these times. It is not possible, therefore, to use 
the excretion data provided to draw reliable inferences regarding the route(s) of 
intake in the two cases. 
 
Tables 3 and 4 show estimated organ doses for X calculated using averaged values 
of intake from Table 1. Assuming intake by ingestion, organ doses are greatest for 
liver and kidneys at up to around 300 mGy and 400 mGy, respectively. Similar doses 
were estimated for liver and kidneys assuming intake by inhalation and in both cases 
(ingestion and inhalation), about half of the total organ doses were estimated to have 
been delivered in the first month after intake and a large proportion of these doses 
were estimated to have been delivered within three months. Lung doses after 
inhalation were estimated to be up to around 4 Gy for intake on 1.11.06 and 5 Gy for 
intake on 16.10.06.  
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Table 1. Polonium-210 intake estimates from sample measurements for individual Xa 
Sample  Sample date Measurement Estimated intake, MBq 
    (Bq/d or Bq) Ingestion on: Inhalation on: 
      01/11/2006 16/10/2006 01/11/2006 16/10/2006 
              
Urine 1 29/11/2006 550 2.9 4.6 3.0 4.4 
Urine 2 30/11/2006 240 1.3 2.1 1.4 2.0 
Urine 3 02/12/2006 459 2.6 4.2 2.7 4.0 
Faeces 29/11/2006 3750 5.7 9.3 5.4 8.3 
Blood 29/11/2006 30000 6.9 11.1 9.8 14.3 
    
     aMeasurements reported by the Federal Medical Biological Agency of the Russian Federation 
to the Litvinenko Inquiry (www.litvinenkoinquiry.org : COM00181001) 
 
 
Table 2. Polonium-210 intake estimates from sample measurements for individual Ya 
 
Sample  Sample date Measurement Estimated intake, MBq  
    (Bq/d or Bq) Ingestion on: Inhalation on: 
    
 
01/11/2006 16/10/2006 01/11/2006 16/10/2006 
    
     Urine 1 29/11/2006 31 0.2 0.3 0.2 0.3 
Urine 2 30/11/2006 53 0.3 0.5 0.3 0.4 
Faeces 29/11/2006 622 0.9 1.5 0.9 1.4 
Blood 1 28/11/2006 2500 0.6 0.9 0.8 1.2 
Blood 2 29/11/2006 2200 0.5 0.8 0.7 1.1 
    
     aMeasurements reported by the Federal Medical Biological Agency of the Russian Federation 
to the Litvinenko Inquiry (www.litvinenkoinquiry.org : COM00182001) 
 
Table 3. Estimated absorbed doses to organs for X, assuming ingestion of 210Po 
  
Assumed 
day of 
intake 
Integration 
period 
                                              Organ dose, mGy   
                                                   
   RBMa Liver Kidneys Spleen Lungs 
   
     1.11.06 30 d 19 98 150 64 4 
 100 d 33 160 240 100 7 
 Total 37 170 260 110 7 
 
      16.10.06 30 d 30 160 240 100 6 
 100 d 53 250 380 170 11 
 Total 60 270 420 180 12 
aRBM: Red Bone Marrow 
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Table 4. Estimated absorbed doses to organs for X, assuming inhalation of 210Po 
 
Assumed 
day of 
intake 
Integration 
period 
                                              Organ dose, mGy   
                                                   
   RBMa Liver Kidneys Spleen Lungs 
   
     1.11.06 30 d 14 74 150 48 2400 
 100 d 27 130 250 86 3500 
 Total 34 150 290 100 3700 
 
      16.10.06 30 d 21 110 230 71 3600 
 100 d 41 190 370 130 5200 
 Total 50 230 430 150 5500 
aRBM: Red Bone Marrow 
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Figure 1. Urinary and faecal excretion of 210Po for X, comparing modelled excretion for 
inhalation or ingestion based on intake corresponding to urine sample 3 (Table 1), and 
measured values during Unithiol treatment 
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Table 5. Assessment of the efficacy of Unithiol treatment of X by comparison of predicted 
excretion of 210Po without treatment to measured excretion following administration of Unithiol 
 
Sample 
Assumed 
date of intake 
  
Modela 
Predicted 
excretion without 
treatmentb, kBq 
Observed 
excretion with 
treatmentb, kBq 
Actual/ 
predicted 
Urine 16/10/2006 U1 9.2 116 12.6 
 01/11/2006 U1 9.1 116 12.8 
 16/10/2006 U2 4.2 116 27.6 
 01/11/2006 U2 4.1 116 28.5 
 16/10/2006 U3 8.4 116 13.8 
 01/11/2006 U3 8.1 116 14.2 
 16/10/2006 F 18.6 116 6.2 
 01/11/2006 F 17.8 116 6.5 
      
Faeces 16/10/2006 U1 26.5 80.3 3.0 
 01/11/2006 U1 26.5 80.3 3.0 
 16/10/2006 U2 12.1 80.3 6.6 
 01/11/2006 U2 11.9 80.3 6.8 
 16/10/2006 U3 24.2 80.3 3.3 
 01/11/2006 U3 23.7 80.3 3.4 
 16/10/2006 F 53.7 80.3 1.5 
 01/11/2006 F 52.0 80.3 1.5 
aModel: the measurement in Table 1 on which estimates of intake and consequent urinary 
and faecal excretion were made, without consideration of the effect of Unithiol 
bConsidering only the treatment period  
 
3.4. Effectiveness of Unithiol treatment to increase 210Po excretion 
Figure 1 illustrates analyses undertaken of the effect of Unithiol in enhancing 
excretion of 210Po in the case of X. FMBA physicians administered Unithiol 
intramuscularly over an extended period from 2nd December 2006 until X was 
discharged from hospital on 28th December 2006. Figure 1 shows modelled excretion 
curves for both urinary and faecal excretion of 210Po, for the two assumed times of 
intake, based on urine sample 3 taken on 2nd December (Table 1) before Unithiol 
treatment was started. Thus, the curves in Figure 1 show estimates of the normal 
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pattern of excretion without chelation therapy and the points are the measured 
excretion values.     
Table 5 shows the results obtained by separate consideration of each intake estimate 
provided in Table 1, comparing model predictions of 210Po excretion in the absence of 
treatment and estimates of actual excretion as shown by measurements during the 
period of treatment.  The possibility that the effects of Unithiol persisted beyond the 
treatment window was not pursued.   As measurements were not available for every 
day during the treatment period, estimates of excretion on these days were 
interpolated using a cubic spline. The data indicate that urinary excretion was 
increased during the treatment period by an average of a factor of 15 and faecal 
excretion was increased by a factor of 4. Thus, it appears that continued 
intramuscular administration of Unithiol is effective in enhancing excretion. However, 
mainly because of the delay between the assumed time of intake and the 
commencement of treatment, the overall effect on retention and the averted dose 
attributable to treatment is modest at less than 10% (probably nearer 5%).      
 
4. Discussion 
Mr Alexander Litvinenko died in a London hospital on 23rd November 2006, after 
having ingested an amount of 210Po on 1st November 2006, estimated to be around 4 
GBq (Nathwani et al 2016, Harrison et al 2017). There is evidence of an earlier intake 
during October 2006 but at a substantially lower level that does not affect the 
interpretation of the fatal consequences of the intake on 1st November (Harrison et al 
2017).  
 
An analysis of over 800 measurements of natural background 210Po in urine gave 
mean and median excretion rates of 13.8 mBq d-1 and 9.3 mBq d-1, respectively 
(Hodgson 2017). Consideration of results for individual countries indicated that UK 
values are generally lower, with a median of around 6 mBq d-1. The amount ingested 
by Mr Litvinenko was therefore about 1012 times greater than natural daily intake 
levels.   
 
Polonium-210 was not established as the cause of Mr Litvinenko’s illness until the 
day of his death. From that time, an intensive survey of contamination of key London 
sites was initiated, together with a large programme of monitoring of people who may 
have become contaminated (Bailey et al 2008, 2010, Maguire et al 2010, Shaw et al 
2010).  Based on an early and rapid review of natural background levels of 210Po in 
urine, a value of 30 mBq d-1 was chosen as an excretion rate above which intake was 
unlikely to be wholly attributable to natural dietary sources.  The extensive analysis 
by Hodgson (2017) showed that while there was a very large range in individual 
values of from 0.3 to 170 mBq d-1, more than 90% of the measurements were less 
than 30 mBq d-1, supporting the early judgment. Separate analyses of data for 
individual countries showed that 95% or more of results were below 30 mBq d-1 in 
most cases, including the UK, but that China and Italy were notable exceptions for 
which more than 20% of values were above this level.       
More than 800 urine samples were analysed as part of the investigation of possible 
contamination resulting from direct contact with Mr Litvinenko or proximity during key 
events. The majority of the measured excretion rates were below 30 mBq d-1, 
providing no evidence of exposure to an artificial source. The majority of 
measurements above 30 mBq d-1 were assessed as corresponding to an effective 
dose of less than 1 mSv (86 cases identified by Bailey et al 2008, 2010). A total of 43 
individuals for whom more detailed assessments were undertaken had assessed 
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effective doses in the range 1 – 10 mSv. Effective doses in the range > 10 mSv – 
100 mSv were recorded for a total of 8 people, mostly staff of one hotel.   
The Litvinenko Inquiry was provided with reports on two additional contaminated 
individuals by an Expert Commission of the Federal Medical and Biological Agency 
(FMBA) of the Russian Federation (reports COM00181001 and COM00182001, 
www.litvinenkoinquiry.org). The FMBA reports included estimates of intake and organ 
doses based on measurements of urinary and faecal excretion of 210Po and 210Po 
concentrations in blood samples. The data are reassessed in this paper, with 
essentially similar results. The two individuals are referred to here as X and Y. 
Estimates of intake by X averaged about 4 MBq for either ingestion or inhalation on 
1.11.06 and 6 – 7 MBq for ingestion or inhalation on 16.10.06. Values for Y were 
estimated to be an order of magnitude lower. Assuming intake by ingestion, 
estimated organ doses for X reached maximum values of up to around 300 mGy for 
liver and 400 mGy for kidneys. Similar doses were estimated for liver and kidneys 
assuming intake by inhalation and in both cases (ingestion and inhalation), about half 
of the total organ doses were estimated to have been delivered in the first month 
after intake and a large proportion of these doses were estimated to have been 
delivered within three months. Assuming intake by inhalation, lung doses were 
estimated to be up to around 4 - 5 Gy.  Estimated effective doses were around 1.5 Sv 
for X and 200 mSv for Y, assuming intake solely by ingestion, 9 Sv and 1 Sv, 
respectively, assuming intake by inhalation, and around 5 Sv and 800 mSv, 
respectively, assuming intake by both routes (1:1).    
 
The chelating agent, Unithiol, was administered intramuscularly to both individuals 
during their time in hospital. Analysis of excretion rates for X indicated that urinary 
excretion was effectively increased during the treatment period by an average of a 
factor of 15 and faecal excretion was increased by a factor of 4. However, mainly 
because of the delay between the assumed time of intake and the commencement of 
treatment, the overall effect on retention and the averted dose attributable to 
treatment appeared to be less than 10% and probably nearer 5%. For a short 
commentary on the use of chelating agents to enhance excretion of 210Po, see 
Jefferson et al (2009).      
 
The very different levels of 210Po intake experienced, ranging from the large intake 
suffered by Mr Litvinenko on 1st November 2006 to the natural background levels to 
which we are all exposed daily, is illustrative of the range of associated risks to 
health, from the certainty of death at the highest doses to the possibility of a very low 
and uncertain risk of cancer associated with the lowest doses.  
 
Mr Litvinenko died three weeks after ingestion of an amount of 210Po estimated as 
around 4 GBq (400 MBq absorbed to blood). Death was the inevitable outcome of 
the radiation doses estimated to have been received by Mr. Litvinenko’s red bone 
marrow, kidneys and liver (Nathwani et al 2016, Harrison et al 2017). Bone marrow 
failure is likely to have been an important contributory cause of death occurring within 
a few weeks of intake, as a component of multiple organ failure.    
 
Autoradiography of hair samples from Mr Litvinenko provided evidence of an earlier 
intake of 210Po during October 2006 at a level of around 1% of the major intake on 1st 
November. As discussed by Harrison et al (2017), it is possible in principle that an 
intake by ingestion at this 1% level, of around 40 MBq  (4 MBq absorbed to blood), 
could have proved fatal over a period of months or years, assuming that no medical 
intervention was instituted. Animal data reviewed by Harrison et al (2007) showed 
death occurring over a period of a few years as a result primarily of kidney damage at 
doses averaging around 1.5 Gy, which compares with an estimated kidney dose to 
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Mr Litvinenko from the first intake, if the second intake had not occurred, of a 
maximum of approaching 3 Gy.    
 
The FMBA of the Russian Federation provided data to the Litvinenko Inquiry on two 
individuals with substantial 210Po contamination (reports COM00181001 and 
COM00182001, www.litvinenkoinquiry.org). Estimates of intake of 210Po by the 
individual with the greatest contamination are about 1000 times less than estimated 
for the major intake by Mr Litvinenko, around 4 – 7 MBq (400 – 700 kBq absorbed to 
blood), depending on when the intake(s) occurred. Estimated organ doses were 
generally below levels that would be expected to cause acute clinically observable 
damage. Maximum estimates of kidney doses were about 400 mGy, below 
thresholds for irreversible acute damage. Lung doses could have been as high as 2 – 
5 Gy if intake had been solely by inhalation and the inhaled chemical form had been 
moderately soluble in the respiratory tract (ICRP Type M). It is possible that such 
high doses to the lungs could result in clinically observable short-term effects. 
However, FMBA clinicians observed that no pathological change in lungs were 
detected (COM00181001 www.litvinenkoinquiry.org). 
 
Below threshold doses for acute deterministic effects, the concern is increased risk of 
stochastic effects, principally cancer. Effective dose is a risk-adjusted dosimetric 
quantity that is used for protection purposes and the control of exposures in relation 
to stochastic risks (ICRP 2007). Although not intended for the purpose of estimating 
risks of exposures, particularly for individuals, it can be used with caution to provide a 
rough indication of risk. Effective dose (Sv) is calculated as the doubly-weighted sum 
of absorbed doses (Gy) to organs and tissues, first using radiation weighting factors 
to correct for the relative biological effectiveness (RBE) of different radiation types 
(e.g. alpha particles compared with gamma rays) in relation to stochastic effects, and 
second, tissue weighting factors to represent fractional contributions of 
organs/tissues to overall detriment from stochastic effects. The nominal risk 
coefficient applied by ICRP to fatal cancer is 5% per Sv (ICRP 2007).   
 
Using the ICRP nominal risk coefficient as an approximate indicator of risk in the 
case of X, estimates of effective dose of around 5 Sv, depending in particular on the 
assumed route of intake (ingestion or inhalation), correspond to a lifetime risk of fatal 
cancer of around 25%, applying as the estimated mortality in a population of people 
exposed at this level. In comparison, incidence rates in developed countries are 
around 40%, with overall fatalities accounting for very roughly half of cases, although 
incidence and survivability vary substantially between cancer types. A 25% increase 
in the risk of fatal cancer represents a substantial increase on background rates, 
approximately doubling lifetime risk. It should be noted that the ICRP risk coefficient 
of 5% per Sv (ICRP 2007) is intended to apply to low dose and dose rate exposures 
and is therefore of questionable applicability to the high organ doses in this particular 
case. However, while this consideration might lead to use of a somewhat higher 
value by up to a factor of two, it is also arguable that the use of a radiation weighting 
factor of 20 for alpha particles is generally conservative (Harrison and Muirhead 
2003, Marsh and Harrison 2014). Ingestion seems a more likely route of intake than 
inhalation for both X and Y, leading to lower estimates of lung dose and effective 
dose (see above), although the possibility of airborne contamination cannot be 
excluded.  
 
To obtain better estimates of risks of radiation-induced cancer, rather than using 
effective dose to provide an approximate indication of risk, requires the use of age-, 
sex- and population- specific risk factors for individual cancer types applied to organ 
absorbed doses (Gy), making due allowance for RBE of alpha particles relative to 
gamma rays for each cancer type. Such detailed analyses are beyond the scope of 
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this paper, but scoping calculations showed similar overall results when considering 
organ-specific risks, although with lower risks when considering age, sex and 
population (about 15% fatal cancer risk compared with about 25%).       
 
In general terms, doses of around 100 mSv represent the limit of reliable direct 
epidemiological observations of statistically significant increases in cancer rates in 
studies of exposed populations (Boice 2014a,b, UNSCEAR 2012a,b). In addition to 
the uncertainties associated with the risk factors derived from such studies, applying 
largely to external exposures to gamma rays, there is the additional uncertainty in the 
present context of their application to internal 210Po exposures for which there is no 
direct information on cancer induction. Support for the assumption of equivalence of 
external radiation exposures and internal alpha particle irradiation, once account is 
taken for RBE, includes quantitative comparisons with risk factors for alpha particle 
emitting nuclides, notably lung cancer associated with inhalation of radon-222 and its 
progeny, but also inhaled plutonium-239, and leukaemia, liver and bone cancer 
induction by other nuclides (Harrison and Muirhead 2003, Marsh and Harrison 2014). 
These comparisons and available experimental evidence support the assumption 
that an estimated effective dose of the order of 100 mSv from 210Po is associated 
with a risk of cancer (around 0.5%) that may in principle be discernible in studies of 
large population groups but corresponds to a small additional risk to individuals. The 
large number of incident cancers in such a group would be very largely attributable to 
causes other than radiation (> 95%).   
 
Effective doses of a few 10s of mSv and less are generally below levels for which 
there is direct evidence of harm in human populations. Studies at such doses have 
focussed on children because of their generally greater sensitivity to radiation-
induced cancer and significant effects have been reported (Pearce et al 2012, 
Mathews at al 2013, Kendall et al 2013). However, caution is required in the 
interpretation of positive results for CT examinations (Pearce et al 2012, Mathews at 
al 2013) because of the potential for reverse causation (UNSCEAR 2013, Walsh et al 
2014). Preliminary findings of an association between natural background gamma 
radiation and childhood leukaemia in Britain (Kendall et al 2013) await further study 
and confirmation. While it is important to pursue sources of direct epidemiological 
evidence of radiation effects in humans at low doses and dose rates (Boice 2014a,b), 
it will always be the case that estimates of risk at very low doses will depend on 
mechanistic understanding and projection of risk estimates derived at higher doses. 
The protection system recommended by ICRP adopts a linear non-threshold (LNT) 
dose response relationship in the control of exposures down to very low levels of 
dose. While this is a pragmatic and convenient approach that allows the addition of 
doses of different magnitude and different types, it is also difficult to challenge as the 
most plausible approach on the basis of our current scientific understanding of the 
mechanisms of radiation action (Preston et al 2003, UNSCEAR 2012c). The 
experimental data and theoretical considerations do not provide firm conclusions 
regarding deviation from linearity. While this issue is of critical importance to ensure 
that protection at low doses is sufficient but not unduly restrictive, in the present 
context of one-off exposures to 210Po, the inferred risk to health associated with 
doses of a few 10s of mSv and less should be regarded as very small and not of 
concern.  
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